#China #Shanghai #GRIT Biotechnology #ASCO 2025 #TIL therapies

Grit Biotechnology Unveils Cutting-Edge Clinical Developments at 2025 ASCO Conference

Grit Biotechnology Co., Ltd., known for its pioneering work in novel immunotherapies, has announced significant clinical updates to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. This year’s conference, which is set to take place in Chicago, Illinois from May 30th to June 3rd, will feature three groundbreaking abstracts focusing on tumor-infiltrating lymphocyte (TIL) therapies that show promise in treating various cancers.

Highlighting Innovative Treatments

Grit Bio will present comprehensive clinical data related to its leading TIL programs, which include:

• - GT101: An unmodified TIL therapy aimed at addressing recurrent and metastatic cervical cancer.
• - GT201: An advanced TIL product that incorporates an armored membrane-bound IL-15 complex for the treatment of diverse solid tumors.
• - GT300: A CRISPR/Cas9 gene-edited dual knockout TIL therapy targeting advanced solid tumors.

The details surrounding these groundbreaking therapies were first made public through the ASCO website on May 22, 2025, and will be shared in poster presentations. For example, the GT101 therapy will be showcased through a Phase 1 study focused on patients with recurrent and metastatic cervical cancer, emphasizing its effectiveness as early as June 1st during the conference.

Presentation Details

GT101

• - Title: Autologous TIL Therapy in Patients with Recurrent and Metastatic Cervical Cancer: A Phase 1 Study
• - Presentation Time: June 1st, 9:00 AM - 12:00 PM CT
• - Poster Number: 431
• - Abstract Number: 5533

GT201

• - Title: Assessing the Safety and Efficacy of GT201: A First-in-Class Autologous TIL Monotherapy in Advanced Solid Tumors
• - Presentation Time: June 2nd, 9:00 AM - 12:00 PM CT
• - Poster Number: 446
• - Abstract Number: 6038

GT300

• - Title: Evaluating the Safety and Efficacy of CRISPR/Cas-Modified TILs (GT300) as Monotherapy in Advanced Solid Tumors
• - Presentation Time: June 1st, 9:00 AM - 12:00 PM CT
• - Poster Number: 511
• - Abstract Number: 5613

Commitment to Innovation

Dr. Yarong Liu, the Founder and CEO of Grit Biotechnology, expressed enthusiasm over the advancements being presented during the conference. “We have harnessed cutting-edge technologies, including advanced gene-editing tools, to enhance the potency and durability of our TIL products,” he stated. “These therapies have showcased promising clinical potential across a range of indications. We remain dedicated to accelerating their clinical development and are actively pursuing global collaborations to ensure that these transformative therapies reach patients around the globe.”

About Grit Biotechnology

Founded in 2019, Grit Bio is an innovative biopharmaceutical enterprise concentrated on immune cell treatments for oncology. Eyeing breakthrough therapies for solid tumors, Grit Bio’s R&D pipeline showcases advancements in TIL therapies. To date, the company has successfully completed several rounds of equity financing and secured backing from prominent venture capital firms. Notably, GT101 is currently undergoing a pivotal Phase II clinical study, indicating the company’s commitment to advancing its research.

Leveraging platforms like StemTexp®, StaViral®, ImmuT Finder®, and KOReTIL®, Grit Bio is focused on generating next-generation gene-edited TIL therapies. With state-of-the-art technology and access to industry resources, Grit Bio aspires to develop transformative therapies that provide new treatment options for cancer patients.

For more detailed information, please visit the company's official website at www.grit-bio.com.

Conclusion

The upcoming ASCO Annual Meeting promises to shed light on the innovative efforts made by Grit Biotechnology as it showcases its advancements in TIL therapies. The company’s strides in harnessing gene editing technology are poised to change cancer treatment, offering hope to patients worldwide.